https://www.selleckchem.com/pr....oducts/hmpl-504-azd6
Complicated vascular anomalies (VAs) may be intractable and uncontrollable by conventional treatments and may result in lethal outcomes. We undertook a prospective, multicenter phase II trial to evaluate the efficacy and safety of sirolimus in pediatric patients with complicated VA. Eligible patients had to be aged 0-14 years and to have complicated VAs. Patients were treated with daily oral sirolimus for 12 months. The primary endpoint was the response measured by sequential volumetric MRI. The secondary endpoints we
Like
Comment
Share
